LSD analogues are laboratory-made relatives of LSD sold online, used mostly as repeated tiny oral doses for mood and mental sharpness. Most are shells the body strips away to release ordinary LSD, inheriting its effects, risks and doses. A smaller engineered group keeps the brain-remodelling effects without the visions, but remains almost entirely in animals. Evidence is early, thin, and commercially entangled; unregulated manufacture means labels are often wrong. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Seated blood pressure | 105–120 / 65–80 mmHg | Determines tolerable dose ceiling |
| Resting heart rate | 50–70 bpm | Baseline for the reliable acute rise |
| Echocardiogram, valve morphology | No regurgitation beyond trace at any valve | Valve status before cumulative 5-HT2B exposure |
| Electrocardiogram, QTc interval | < 440 ms men, < 450 ms women | Rhythm vulnerability flagged by computational models |
| ALT and AST | ALT 10–26 U/L women, 10–30 U/L men; AST 10–26 U/L | Hepatic capacity to clear the released compound |
| Complete blood count | Haemoglobin 13.5–15.0 g/dL men, 12.5–14.5 women; platelets 200–300 ×10⁹/L | Predicted blood-cell toxicity for 1P-LSD and 1B-LSD |
| eGFR with creatinine and cystatin C | > 90 mL/min/1.73 m² | Clearance of downstream metabolites |
| hs-CRP | < 0.5 mg/L | Baseline for the speculative anti-inflammatory claim |
| Prolactin | Men < 15 ng/mL; women < 20 ng/mL | Sustained endocrine effect of ergoline exposure |
| CYP2D6 genotype | Normal metaboliser (two functional copies) | Predicts exposure and duration at a given dose |
Cadence: Blood pressure and heart rate before and 2 hours after each dose; blood panel at 3 months into a repeated regimen, then every 6–12 months; echocardiogram at 24 months when dosing more often than monthly.